CB heads into its October 20 earnings with short sellers backing away and options traders more bullish than they've been in months — a setup that contrasts with modest analyst caution at the stock's current price.
The clearest directional story this week is the sustained retreat of short sellers. Short interest has fallen 25% over the past month to just 0.83% of the free float — a level so low it barely registers as a bearish position. The weekly decline alone ran to 11%, with shares short dropping from around 3.77 million to 3.25 million. Borrow costs have followed, halving over the week to just 0.20%, and availability is effectively unlimited — the lending pool is barely touched, with nearly 344 million shares available to borrow. There is no squeeze pressure here, and no sign of fresh short conviction building.
Options positioning reinforces the constructive tone. Call demand has outstripped puts noticeably: the put/call ratio has dropped to 0.73, about one standard deviation below its 20-day average of 0.78. That's not an extreme reading, but the direction of travel is clear — the ratio spent most of August above 0.80 and has slid steadily lower as the stock gained 1.6% on the week to close at $341.86. The 52-week low on the PCR is 0.46, so there remains room for calls to become even more dominant, but for now the positioning looks modestly optimistic rather than complacent.
The Street's view is more measured. Mizuho trimmed its target today from $352 to $347, keeping a Neutral rating — the third cautious signal in recent weeks from mid-tier analysts running targets close to or below the current price. Morgan Stanley lifted its target to $360 at Equal-Weight in August, and JP Morgan raised to $374 in July, but the consensus message from the majority of coverage is "fairly valued" rather than a strong buy. The mean analyst target of $366 implies about 7% upside from current levels. The P/E sits at just under 12x and price-to-book at 1.53x — undemanding multiples for a franchise of this quality, and consistent with the bull case that Chubb trades at attractive valuations given its ROE profile and global diversification. The bear case rests on premium growth: the most recent quarter saw P&C net written premiums grow just 1% on a constant-currency basis, weighed down by heavy large-account non-renewals and reduced E&S exposures. The dividend score ranks in the 98th percentile against the universe, and the $1.02 quarterly payment announced in May underlines management's confidence in the cash-generation story.
The institutional register is worth a brief note. Berkshire Hathaway remains the largest single holder at 8.9% of shares, unchanged on the most recent disclosure. BlackRock added roughly 1.2 million shares in its latest filing, while FMR (Fidelity) added over 1.2 million as well — passive and active buyers both incrementally adding weight. On the insider side, the 90-day picture shows net open-market selling of around $6.2 million, driven by a $3.1 million disposal from an EVP in late July and a $1.9 million director sale in August. None of these are red-flag scale for a stock trading near $340, but the absence of any open-market buying from senior management is worth keeping in mind as the stock approaches its year-to-date high.
Peers mostly moved in line this week. TRV led the insurance group with a 3.4% weekly gain, EG added 2.6%, and AFG picked up 2.1%, suggesting sector tailwinds rather than a CB-specific catalyst behind the 1.6% advance. HIG lagged at +0.3%, the one name that underperformed meaningfully within the group.
The October 20 earnings date is the next pivot. After the most recent print in late July the stock fell roughly 2.6% on the day before recovering to close the five-day window up 3.1%, meaning the initial reaction was negative but shorter-lived than the subsequent drift suggests. Whether premium growth can re-accelerate — or at least stabilise — from the 1% pace of Q2 is the question the Street will be pressing hardest.
See the live data behind this article on ORTEX.
Open CB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
